SYMPOSIA
SYMPOSIA
SYMPOSIA
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Poster Presentations<br />
schizophrenia patients.<br />
Methods: Ninety one schizophrenic patients (38 female, 53 male) receiving antipsychotics for at least one year were included in the study.<br />
The parameters associated with MS were as follows: Body mass index, body weight, waist circumference, systolic and diastolic blood<br />
pressure, fasting blood glucose, insulin, serum triglycerides, HDL cholesterol levels, and the insulin resistance as calculated by using the<br />
value HOMA (homeostasis model assessment). The criteria were based on ATP-III criteria for metabolic syndrome (Adult Treatment Panel<br />
III). Statistical analysis was performed by using SPSS 17.0 (for Windows).<br />
Results: Serum triglyceride levels were inversely correlated with serum direct bilirubin (p=.006) and positively correlated with indirect/<br />
direct bilirubin ratio (p =. 002). Serum HDL levels (p=.018) showed a significant positive correlation with indirect/direct bilirubin ratio.<br />
Waist circumference (p=.048) showed a significant negative correlation with serum total bilirubin. The levels of insulin (p =.038) and value<br />
of HOMA (p =.015) were inversely correlated with serum direct bilirubin.<br />
The rate of metabolic syndrome was significantly lower in the patients with highest quartile (75-100) of the serum direct bilirubin levels<br />
than the other quartiles (p=.022).<br />
In these patients, the ratio of the patients that meet criteria for metabolic syndrome according to levels of the fasting triglyceride (p=.013)<br />
and HDL (p=.040) was significantly lower than others. Additionally, the means of body weight (p=.026), waist circumference (p=.022), and<br />
serum triglyceride levels (p=.039) of these patients were found significantly lower.<br />
Conclusions: In this study we found that bilirubin levels are associated with metabolic syndrome and its parameters and high levels of<br />
serum direct bilirubin may be associated with the lower risk for MS in schizophrenia patients; similar to the healthy individuals (1,2,4).<br />
Our study is the first study investigating this issue. Our results may be important for the following aspects: High serum direct bilirubin<br />
levels may serve as an easily applicable, inexpensive marker indicating lower MS risk for schizophrenic patients. Additionally, it may be<br />
possible to prevent antipsychotics induced metabolic side effects by avoiding the drugs with higher risk for MS, in the patients with low<br />
levels of direct bilirubin. Due to the relatively limited number of patients and cross-sectional nature, our results required to be confirmed<br />
by longitidunal studies with larger samples.<br />
Key words: Schizophrenia, metabolic syndrome, bilirubin, antipsycotic drug<br />
Bulletin of Clinical Psychopharmacology 2011;21(Suppl. 2):S179-80<br />
[PP-096] Ref. No: 293<br />
Olanzapine abuse: A case report<br />
Neslihan Akkişi Kumsar, Atila Erol<br />
Sakarya Training and Research Hospital, Sakarya, Turkey<br />
E-mail: drneslihanakkisi@yahoo.com<br />
Introduction: Olanzapine is a thienobenzodiazepine which specifically blocks 5-HT2A and D2 receptors and additionally blocks<br />
muscarinic (M1), H1, 5-HT2C, 5-HT3.5-HT6, a l, and D4 receptors. It has greater affinity for 5-HT2 receptors than for D2 receptors (Kelly,<br />
Conley & Carpenter 2005). Olanzapine has consistently been found to be significantly superior to placebo and comparable with, or<br />
superior to, haloperidol for the treatment of overall, positive, and negative symptoms of schizophrenia. In this case, we want to report a<br />
case of olanzapine abuse.<br />
Case Report: A 48-year old, primary school graduate, married, female patient was admitted to our psychiatry clinic with tachycardia,<br />
insomnia, and anxiety. In psychiatric assessment, she mentioned that her symptoms have been similar for 15 years and in the last 3 years<br />
she has used citalopram 40 mg/d and olanzapine 10 mg/d and after this treatment her symptoms decreased. During psychiatric treatment<br />
when her consequent doctor wanted to stop the olanzapine treatment, she did not succeed and the patient had anxiety, insomnia, and<br />
anger and reported decreased symptoms after using the drug again<br />
Discussion: Besides medications with obvious abuse potential such as benzodiazepines and methyphenidate and other stimulants, abuse<br />
of a number of commonly prescribed psychiatric medications has been reported. The abuse of anticholinergic drugs was first reported<br />
in 1960 with the description of a patient, who increased her trihexyphenidyl to achieve antidepressant and euphoriant effects. Recently,<br />
abuse of quetiapine for its sedative and anxiolytic effects has been reported. The abuse risk of quetiapine has been also reported in our<br />
country and Kaya et al. studied the abuse risk of quetiapine with prisoners. In the literature there are only two cases of olanzapine abuse.<br />
Key words: Abuse, olanzapine<br />
Bulletin of Clinical Psychopharmacology 2011;21(Suppl. 2):S180<br />
S180 Bulletin of Clinical Psychopharmacology, Vol: 21, Supplement: 2, 2011 - www.psikofarmakoloji.org